Accentia Biopharmaceuticals, Inc., a biotechnology

Accentia Biopharmaceuticals, Inc., a biotechnology company, primarily engages in the discovery, development, and commercialization of immunotherapies to treat autoimmune related diseases and cancer in the United States. The company develops Cyrevia as a system of care for various autoimmune diseases; BiovaxID as a personalized therapeutic cancer vaccine to treat non-Hodgkin’s lymphoma, follicular lymphoma, mantle cell lymphoma, and other B-cell cancers; and SinuNasal lavage system as a medical device for chronic sinusitis. It also manufactures and sells a range of cell culture systems used for the production cell culture products, including HF Primer, a cell culture system for producing small, research, and development quantities of cell culture products from mammalian cell lines; Multi-6 for producing six monoclonal antibodies; AutovaxID, an automated cell culture system for production of personalized cell-based treatments and various additional vaccines; Acusyst-miniMax system, which offers two single-use disposables options to meet various production requirements; Acusyst-Maximizer, a system for process development and routine productions; and Acusyst-Xcellerator, a production-scale cell culture system. In addition, the company manufactures mammalian cell culture products such as, whole cells, recombinant and secreted proteins, and monoclonal antibodies, as well as provides related services in developing cell production process protocols, cell line optimization, cell culture production optimization, media evaluation, and other related services. Further, it sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies. The company provides its cell culture products and services to biopharmaceutical and biotechnology companies, medical schools, universities, research facilities, hospitals and public and private laboratories. Accentia Biopharmaceuticals, Inc. was founded in 2002 and is headquartered in Tampa, Florida.